134 related articles for article (PubMed ID: 37795760)
1. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
2. Exploring
Mansoor A; Akhter A; Hamidi M; Roshan TM; Shabani-Rad MT; Stewart D
Anticancer Res; 2023 Nov; 43(11):4801-4807. PubMed ID: 37909960
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
4. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
[TBL] [Abstract][Full Text] [Related]
6. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
8. Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.
Qu Z; Zhang T; Gao F; Gong W; Cui Y; Qiu L; Qian Z; Zhou S; Meng B; Ren X; Li L; Wang X; Zhang H
Biomed Res Int; 2022; 2022():4379556. PubMed ID: 35655476
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
[TBL] [Abstract][Full Text] [Related]
11. A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.
Green MR; Jardine P; Wood P; Wellwood J; Lea RA; Marlton P; Griffiths LR
BMC Cancer; 2010 May; 10():195. PubMed ID: 20462409
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10
Azoulay D; Cohen HI; Dementiev E; Eshel E; Akria L; Shaoul E; Horowitz N
Cytometry B Clin Cytom; 2020 Sep; 98(5):449-453. PubMed ID: 31816181
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Barraclough A; England JT; Villa D; Wight J; Hapgood G; Conn J; Doo NW; Li EW; Gilbertson M; Shaw B; Bishton MJ; Saeed M; Ratnasingam S; Abeyakoon C; Chong G; Wai SH; Ku M; Lee HP; Fleming K; Tam C; Douglas G; Cheah CY; Ng ZY; Rolfe T; Mills AK; Hamad N; Cashman H; Gleeson M; Narayana M; Hawkes EA
Haematologica; 2023 Sep; 108(9):2444-2453. PubMed ID: 36815381
[TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
[TBL] [Abstract][Full Text] [Related]
16. Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.
Yuan J; Liu H; Hu S; Miranda RN; Xu X; Bayerl MG; Artymiuk CJ; Berg H; King RL; Shi M; He R; Viswanatha D; Medeiros LJ; McPhail ED
Hum Pathol; 2023 Nov; 141():22-29. PubMed ID: 37634651
[TBL] [Abstract][Full Text] [Related]
17. [Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].
Vogelsberg A; Steinhilber J; Mankel B; Federmann B; Schmidt J; Montes-Mojarro IA; Hüttl K; Rodriguez-Pinilla M; Baskaran P; Nahnsen S; Piris MA; Ott G; Quintanilla-Martinez L; Bonzheim I; Fend F
Pathologe; 2021 Dec; 42(Suppl 2):122-128. PubMed ID: 34671837
[TBL] [Abstract][Full Text] [Related]
18. In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Aya-Bonilla C; Camilleri E; Haupt LM; Lea R; Gandhi MK; Griffiths LR
BMC Genomics; 2014 May; 15(1):390. PubMed ID: 24885312
[TBL] [Abstract][Full Text] [Related]
19. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
20. [Diffuse large B-cell lymphoma developed newly after 9-year remission of a follicular lymphoma].
Hirano T; Tsuji T; Yamasaki H; Toyozumi Y; Arima N; Tsuda H
Rinsho Ketsueki; 2016 Feb; 57(2):171-4. PubMed ID: 26935635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
